Novartis Kesimpta six-year efficacy data show substantial benefits in recently diagnosed treatment-naE¯ve people with relapsing multiple sclerosis

Continuous Kesimpta treatment for up to six years showed sustained efficacy in recently diagnosed ([less than or equal to]3 years) treatment-naȯve people living with relapsing multiple sclerosis (RMS) in an [...]